Quest Diagnostics Incorporated — Form 8-K
Filing date: October 6, 2026. This filing reports an executive role transition and planned retirement; it does not provide quarterly or annual operating results.
Business context and event
Catherine T. Doherty will retire in July 2027. Effective November 1, 2026, she will transition to an Executive Vice President role with responsibilities including health systems, the company’s Corewell Health joint venture, and Project Nova, a multi-year modernization of “Order to Cash” processes and related technology.
Compensation details
- Annual base salary remains $650,000.
- Annual incentive compensation remains targeted at 80% of base salary under the Senior Management Incentive Plan.
- An equity award with a target value of $1,200,000 is scheduled for a November 3, 2026 grant date. It is allocated entirely to restricted stock units and is subject to terms substantially similar to 2026 annual long-term incentive awards for other senior executives.
Financial performance and outlook
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or operating guidance information. It does not quantify the financial impact of the role transition or Project Nova.
Important facts to verify
- Whether Ms. Doherty’s retirement occurs as planned in July 2027.
- Whether the equity award is granted on November 3, 2026, and its final terms.
- Any subsequent disclosures about leadership succession, Project Nova, or the Corewell Health joint venture.